Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

26
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
26
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

987
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
987
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

847
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
847

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.

Journal of clinical medicine·2026
Same author

Reassessing Agreement Between Point of Care and Laboratory Triglyceride Measurements in High Risk Pregnancy.

Endocrinology, diabetes & metabolism·2026
Same author

Trends of Acute Pericarditis-Related Mortality in the United States from 1999 to 2023: An Observational Analysis.

Avicenna journal of medicine·2026
Same author

Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis-right-to-reply.

The Journal of antimicrobial chemotherapy·2026
Same author

Safety and Efficacy of Lorundrostat in Uncontrolled Hypertension: A Systematic Review and Meta-Analysis.

Journal of cardiovascular pharmacology·2026
Same author

Critical Appraisal of Self-Supervised Contrastive Pretraining for Extreme Few-Shot ECG Classification.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·2026

Related Experiment Video

Updated: Sep 10, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

Colchicine as an Adjunct Therapy Postablation for Atrial Fibrillation: A Systematic Review and Meta-analysis.

QuraTul Ain1, Tahira Irshad2, Mahnoor Usman2

  • 1From the Department of Cardiology, Shifa College of Medicine, Shifa Tameer e Millat University, Islamabad, Pakistan.

Cardiology in Review
|August 22, 2025
PubMed
Summary

Colchicine, an anti-inflammatory drug, significantly reduces atrial fibrillation (AF) recurrence after catheter ablation. While it increases gastrointestinal side effects, it offers a promising strategy to improve ablation success rates.

Keywords:
anti-inflammatory therapyatrial fibrillationcardiac electrophysiology and arrhythmiascatheter ablationcolchicinemeta-analysisrandomized controlled trialssystematic review

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.4K

Related Experiment Videos

Last Updated: Sep 10, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.8K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.4K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) recurrence post-catheter ablation is a significant clinical issue.
  • Postprocedural inflammation is a key factor contributing to AF recurrence.
  • Colchicine, an anti-inflammatory agent, is being investigated to mitigate this recurrence.

Purpose of the Study:

  • To evaluate the efficacy and safety of colchicine in preventing AF recurrence after catheter ablation.
  • To assess colchicine's impact on secondary outcomes like pericarditis and side effects.

Main Methods:

  • A meta-analysis of 8 studies (N=3784) including randomized controlled trials (RCTs) and observational studies.
  • Literature search across PubMed, Embase, Scopus, and Cochrane databases up to March 2025.
  • Data pooled using random-effects model with subgroup and sensitivity analyses.

Main Results:

  • Colchicine significantly reduced AF recurrence (RR=0.75, P=0.04), with a stronger effect in RCTs (RR=0.60, P=0.0004).
  • Increased risk of gastrointestinal side effects was observed (RR=2.34, P=0.01).
  • No significant effect on pericarditis, hospitalizations, or composite outcomes.

Conclusions:

  • Colchicine demonstrates efficacy in reducing AF recurrence post-ablation, especially in RCTs.
  • Gastrointestinal intolerance is a concern, but colchicine may be a valuable adjunctive therapy.
  • Further large-scale trials are needed to confirm efficacy and optimize dosing.